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Kallikrein-related peptidases (KLKs) form a cancer-related ensemble of serine proteases. This
multigene family hosts the most widely used cancer biomarker that is PSA-KLK3, with millions
of tests performed annually worldwide. The present report provides an overview of the
biomarker potential of the extended KLK family (KLK1-KLK15) in various disease settings and
envisages approaches that could lead to additional KLK-driven applications in future molecular
diagnostics. Particular focus is given on the inclusion of KLKs into multifaceted cancer
biomarker panels that provide enhanced diagnostic, prognostic and/or predictive accuracy in
several human malignancies. Such panels have been described so far for prostate, ovarian,
lung and colorectal cancers. The role of KLKs as biomarkers in non-malignant disease
settings, such as Alzheimer’s disease and multiple sclerosis, is also commented upon.
Predictions are given on the challenges and future directions regarding clinically oriented
KLK research.
KEYWORDS: biomarker panel • cancer diagnosis • cancer prognosis • kallikrein-related peptidases • KLK • molecular
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Kallikrein-related peptidases: serine
proteases with extensive implication
in human (patho)physiology & unique
biomarker capabilities
Prostate-specific antigen (PSA) or kallikrein-
related peptidase 3 (KLK3) is the most widely
recognized member of the tissue kallikrein and
kallikrein-related peptidases gene family
(KLKs) [1]. PSA–KLK3 has been broadly used
as a prostate cancer biomarker for almost three
decades [2–6].
KLKs, located on chromosome 19q13.3–
q13.4, comprise 15 gene members (KLK1–
KLK15) [1] that have been suggested, in a
plethora of studies, as promising disease
biomarkers [7–9]. Efforts have also been made
in order to evaluate the therapeutic potential
of KLKs through various approaches that
include engineered inhibitors, prodrugs activa-
tion and KLK-driven immunotherapy [10,11].
Perhaps, the continuously reported broad
role of KLKs as biomarkers is a reflection of
the important functions they serve in human
physiology. KLKs share notable similarities at
the levels of gene/protein structure (five coding
exons that encode for inactive zymogens), pro-
tein activity (trypsin or chymotrypsin like) and
biological regulation of their gene expression
(by steroid hormones, methylation, histone
modification, miRNAs) and enzyme activity
(cleavage activation, inhibition by endogenous
molecules) [12–14]. Under physiological condi-
tions, KLKs act on their substrates, which
include growth factors, hormones, proteases
and cell signaling molecules, in order to
orchestrate important body functions such as
skin homeostasis, blood pressure regulation,
semen liquefaction and neuronal plasticity
[13–16]. Looking at the other side of the coin,
deregulation of KLK function can trigger the
manifestation of severe diseases. KLKs have
been primarily studied as molecules that can
influence the initiation and progression of
human malignancies [9–12,16]. Nonetheless, their
involvement has also been thoroughly investi-
gated in neurodegenerative/neuroinflammatory
disorders [15–18] and, particularly, skin diseases
[19–22].
The present report provides an overview of
the KLK biomarker potential in various disease
settings and envisages approaches that increase
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the probabilities of introducing additional KLK-driven applica-
tions in future molecular diagnostics. Expected challenges and
predicted directions in clinically oriented KLK research are also
commented upon.
KLKs as cancer biomarkers: from PSA–KLK3 to the
extended KLK family
Clinical oncology has been radically evolved after the incorpo-
ration of biological tumor markers in the management of
human malignancies. Representative examples of the few tumor
biomarkers that have succeeded in reaching routine clinical
practice include the HER2 gene amplification and OncotypeDx
gene expression panel tests as predictive biomarkers for breast
cancer, CA125 for ovarian cancer monitoring, BRAF mutation
assessment for melanoma and PSA testing for prostate cancer
screening and monitoring [23,24].
PSA: a successful, yet controversial, cancer biomarker
The influence of PSA testing on clinical decision making, both
in a positive and negative sense, is so unique that in the history
of oncology, it is logical to categorize prostate cancer manage-
ment in a pre-PSA period, the current PSA period, as well as a
post-PSA period, which is agonizingly anticipated [23,25].
The first studies describing the usefulness of PSA as a
prostate cancer biomarker showed its utility as a disease mon-
itoring and recurrence prediction tool and in 1986 received
US FDA approval for this use [4,26]. The use of PSA measure-
ments still remains the gold standard in defining biochemical
relapse and thus disease recurrence [27]. However, after its ini-
tial approval, PSA testing was also applied for diagnostic pur-
poses. In the following years, detection of prostate cancer
increased spectacularly in the USA. The broad application of
PSA testing as a screening strategy in asymptomatic men
(FDA approved for this use in 1994) led to an impressive
decrease in the cases diagnosed with advanced disease [28,29].
Nonetheless, all these important benefits came with a price.
PSA serum levels are increased not only in clinically relevant
prostate cancer, but also in every lesion that alters prostate
gland’s architecture including benign conditions and clini-
cally indolent cancer. The widespread use of PSA testing led
to more men with benign conditions being biopsied and to
more men with no life-threatening tumors undergoing
unnecessary radical treatment [23,30,31]. Two large-scale trials
that investigated the effect of PSA screening per se in reduc-
ing prostate cancer mortality (Prostate, Lung, Colorectal, and
Ovarian [PLCO] cancer screening trial and European Ran-
domized Study of Screening for Prostate Cancer [ERSPC])
produced conflicting results. The PLCO trial [32], which was
later criticized due to contamination of the unscreened arm,
reported no benefit from screening, whereas ESPRC [33]
reported a decrease in prostate cancer mortality [23,30]. The
abovementioned data led the US Preventive Services Task
Force to recommend against PSA screening, a decision that
provoked extensive discussion and heavy criticism [23,34,35]. It
seems that PSA testing as we know it may have gone full
circle and its initial use for disease monitoring happens to be
also the most suitable. The introduction of additional bio-
markers that would limit the PSA-driven overdiagnosis/
overtreatment and that could identify patients who will indeed
benefit from hormonal and chemotherapy represents a clinical
necessity. A systematic, multiphase procedure is needed in
order for novel prostate cancer biomarkers to reach clinical
practice. This carefully designed process should begin from the
initial evidence-based discovery stage and continue with rigor-
ous validation phases, including independent cohorts, retro-
spective and prospective studies, before finally reaching large-
scale population trials [36].
Normalizing PSA to the prostate gland volume, determin-
ing changes in PSA measurements over time, measuring per-
centage of free PSA (%fPSA), complexed PSA, as well as the
use of the more recently (2012) FDA-approved tests, such as
the PCA3 urine test and the combined serum measurements
of -2proPSA, free PSA and total PSA (calculated as prostate
health index), have been proposed as next steps for improving
the biomarker capabilities of PSA. Artificial neural networks,
nomograms and logistic regression models can also help
toward this direction [23,37–39]. Despite the reported improve-
ments in the diagnostic performance of PSA by the afore-
mentioned approaches, it is believed that a more radical
paradigm shift is still needed.
As discussed in detail below (in ‘KLKs in cancer biomarker
panels: A more realistic and promising approach for routine
clinical practice’ section), the introduction of novel molecular
markers belonging to the extended KLK family, through a bio-
marker panel strategy, could provide considerable improve-
ments for prostate cancer screening.
Beyond PSA: the capacity of individual KLKs as biomarkers
for human malignancies
Papers published on the association of KLKs with human
malignancies (1933–2012) have been calculated to amount to
the astonishing sum of 28,744 [40]. Every single member of the
KLK gene family has been evaluated and proposed as a mean-
ingful serum and/or tissue marker for at least one human
malignancy [8,9].
Recently published review articles thoroughly describe the
biomarker potential of the KLK gene family in urogenital and
reproductive organ malignancies [41,42], gastrointestinal malig-
nancies [43], lung, brain, head and neck cancers, and acute lym-
phoblastic leukemia [7–9]. A book volume dedicated to the
biomarker potential of KLKs for cancer diagnosis, prognosis
and treatment response prediction/monitoring has also been
published [40]. A brief overview of this information is conveyed
in TABLE 1.
The characterization of the extended cancer-related KLK
family, including several alternative mRNA transcripts and pro-
tein isoforms, the comprehensive expression profiling of KLKs
at different levels (mRNA, protein) and different disease set-
tings (malignant and nonmalignant), as well as the significant
improvements in the sensitivity and specificity of molecular
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assays and reagents for KLK determination, raised expectations
that the detailed information of KLK genes and proteins will
trigger the identification of several potential tumor markers.
The initial hopes and predictions have been fulfilled to a con-
siderable extent, but still need to be realized into everyday
clinical decision making.
KLKs in cancer biomarker panels: a more realistic &
promising approach for routine clinical practice
A series of genomic and proteomic analyses have robustly
demonstrated that cancer is an extremely heterogeneous dis-
ease in terms of morphological and biological features, clini-
cal disease manifestation and progression, as well as response
to currently available therapeutics [44]. Thus, it would be rea-
sonable to foresee that no single biomarker will be ever capa-
ble of providing accurate enough information for cancer
diagnosis, prognosis or treatment response prediction. The
current trend for maximizing the clinical effectiveness of bio-
markers, and thus compensating for their low incorporation
rates into clinical practice, is the identification of combinato-
rial biomarker panels. KLKs have already been identified as
valuable composites of such panels for prostate, ovarian, lung
and colorectal cancers.
Perhaps, the most intriguing and well-validated data derived
from a series of studies regarding the identification of a four-
kallikrein serum panel consisting of total, free and intact PSA,
as well as KLK2, for prostate cancer management. The above-
mentioned ‘kallikrein panel’ can effectively predict the result of
a prostate biopsy in both unscreened and previously screened
men. The application of the ‘kallikrein panel’ could appropri-
ately tackle the overdiagnosis and overtreatment complications
deriving from PSA-based screening. It is a straightforward
approach that makes use of routine laboratory tests and current
standard of care in order to reduce the number of unnecessary
prostate biopsies, and accompanying complications, with
enhanced sensitivity (especially in high-grade tumors) and spec-
ificity (reduced detection rates of clinically indolent low-grade
tumors) [45–47]. Moreover, statistical models based on the
‘kallikrein panel’ could effectively replace invasive procedures,
such as transrectal ultrasonography and digital rectal examina-
tion, in predicting prostate biopsy outcome [48]. Another essen-
tial problem that the ‘kallikrein panel’ addresses is the
economic impact of repeated unnecessary prostate biopsies that
cannot be overlooked during the times of global economic cri-
sis. A future application of the ‘kallikrein panel’ in routine
diagnostics would reduce the unnecessary biopsies performed in
Table 1. The biomarker potential of individual KLKs in human malignancies.
Cancer type Clinical relevance Ref.
Prostate Diagnosis: KLK2, KLK3, KLK11 [41]
Prognosis/Prediction: KLK2, KLK3, KLK4, KLK5, KLK11, KLK14, KLK15
Ovarian Diagnosis: KLK5, KLK6, KLK8, KLK10, KLK11, KLK13, KLK14 [41,42,55]
Prognosis/prediction: KLK4, KLK5, KLK6, KLK7, KLK8, KLK9, KLK10, KLK11, KLK13, KLK14, KLK15
Breast Diagnosis: KLK3, KLK5, KLK10, KLK14 [41,104]
Prognosis/Prediction: KLK3, KLK4, KLK5, KLK7, KLK9, KLK10, KLK12, KLK13, KLK14, KLK15
Lung Diagnosis: KLK5, KLK7, KLK8, KLK10, KLK11, KLK12, KLK13, KLK14 [8,105]
Prognosis: KLK6, KLK8, KLK11, KLK13
Colorectal Prognosis: KLK4, KLK5, KLK6, KLK7, KLK8, KLK10, KLK11, KLK13, KLK14 [43]
Gastric Diagnosis: KLK6 [43,106]
Prognosis: KLK6, KLK10, KLK11, KLK12, KLK13
Endometrial Diagnosis: KLK6, KLK10 [42]
Prognosis: KLK6
Cervical KLK7 (increases with the severity of lesions) [42]
Testicular Prognosis: KLK5 [42]
Kidney Prognosis: KLK6 [42]
Urinary bladder KLK5, KLK6, KLK9 (increased in invasive tumors) [107]
Head and neck Prognosis: KLK4, KLK7, KLK11 [8]
Pancreatic Prognosis: KLK6, KLK7, KLK10 [9,43]
Intracranial tumors Prognosis: KLK6, KLK7 [9,108]
KLK: Kallikrein-related peptidases.
Predictions for the future of KLKs in molecular diagnostics Review
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the USA up to 56%, without compromising standards of care;
this translates to approximately US$1.12 billion savings per
year for the US health care system [49].
Multivariate models and/or artificial neural networks com-
bining serum KLK2, %fPSA and PSA levels could provide, to
some extent, an improved discrimination between CaP and
BPH patients. Similar approaches using serum KLK11,
%fPSA, MIC-1, MIF, prostate volume or age can also enhance
BPH and CaP discrimination. Logistic regression models have
demonstrated the potential of serum IGF-1/fPSA ratio and
PSP94–fPSA combination for the differential diagnosis of
benign and malignant prostate tumors [38]. The incorporation
of a number of single nucleotide polymorphisms (SNPs) in a
nomogram also containing PSA, %fPSA, age and other clinical
can improve the positive predictive value of PSA testing [50].
Regarding ovarian cancer, initial studies had demon-
strated that serum KLK6 [51] and KLK10 [52] measurements
can be used to enhance the diagnostic sensitivity of CA125
in early disease stages. A later study revealed improved diag-
nostic properties for the combination of serum KLK10 and
CA125 over CA125 alone [53]. Additionally, combinations
between serum KLK6 and KLK10 with CA125 and age
provided improvements in the discriminatory accuracy for
patients harboring ovarian tumors compared with single
marker use [54]. A panel of eight KLKs (KLK5, KLK6,
KLK7, KLK8, KLK10, KLK11, KLK13 and KLK14) deter-
mined in effusion samples produces remarkable areas under
the curve (AUCs) of 0.99 and 0.96 for the discrimination
of cancer from benign cases and ovarian cancer from other
malignancies, respectively [55]. Performed in tissue samples,
a panel of KLK6, KLK13 and MUC16 (encoding for
CA125) mRNA levels increases the detection sensitivity for
early stage ovarian cancer and the negative predictive value
compared with MUC16 alone [56]. In cytosolic extracts, the
combination of CA125, B7-H4, KLK4, KLK5, KLK7,
KLK8 and KLK11 and the combination of CA125, KLK8,
KLK10 and KLK13 protein levels can effectively distinguish
between ovarian cancer and benign tumors, and between
primary ovarian cancer and primary tumors metastatic to
the ovary, respectively [57].
KLK-based biomarker panels with prognostic significance
can also be proven extremely helpful in ovarian cancer deci-
sion making. A combination of KLK6 and KLK13 tissue pro-
tein levels, ascites volume and nuclear grade can accurately
predict (AUC = 0.833) the presence of residual tumor after
surgery and thus instruct the administration of preoperative
chemotherapy [58]. The combined determination of KLK13,
KLK6, KLK8 protein levels in ovarian cytosolic extracts,
disease stage and debulking status can efficiently identify
patients’ response to chemotherapy (AUC = 0.91). Similarly,
impressive predictive capabilities have been identified regard-
ing 1-year progression-free survival (AUC = 0.90) for a
combination of KLK6, KLK8, KLK11, KLK1 and clinical
variables (i.e., stage, debulking success, chemotherapy response),
and 5-year progression-free survival (AUC = 0.93) for a
combination of KLK6, KLK7, KLK11, KLK14, B7-H4 and
clinical variables [57]. Serum-based multiparametric panels have
also been constructed and could offer valuable prognostic infor-
mation regarding 1-year survival (KLK7, KLK10, B7-H4 and
Spondin-2), 1-year disease progression (CA125, KLK7, KLK8
and Spondin-2) and chemotherapy response (CA125, KLK5
and KLK7) [59].
In non-small-cell lung cancer (NSCLC), the study of
Planque et al. has demonstrated the diagnostic capabilities
(AUC = 0.90) of combined KLK4, KLK8, KLK10, KLK11,
KLK12, KLK13 and KLK14 serum measurements for the
discrimination between NSCLC patients and healthy indi-
viduals. Another model that includes serum KLK8, KLK11,
KLK12, KLK13, KLK1 as well as gender and smoking pro-
duced an AUC of 0.92 [60]. Several combinatory assessments
of KLK mRNA expression levels can provide important
prognostic information regarding the overall survival (OS) of
NSCLC patients. The KLK8 alternative transcript 4/KLK11
mRNA ratio in lung cancer is a strong independent predic-
tor of poor OS, showing better prognostic performance even
from clinical stage [61].
In colorectal cancer, the combination of tissue protein levels
of KLK14, and KLK8, KLK10, KLK14, KLK15, with clinical
parameters (age and TNM stage) leads to an increased predic-
tive potential of 1-year and 5-year OS, respectively, compared
with clinical parameters alone [62].
Regulation of KLK expression by miRNAs & DNA
methylation: epigenetic mechanisms with great
translational potential
Determinations of DNA methylation status and miRNA
expression levels are regarded as valuable biological tumor
markers. They can be easily assessed in body fluids, such as
blood or urine, as well as in archival material (formalin-fixed
paraffin-embedded tissues) that is accompanied by invaluable
clinical follow-up information [63–65].
The miRNA–KLK axis of interaction has been described
so far in prostate cancer [66], ovarian cancer [67] and renal cell
carcinoma [68]. Several miRNAs that are deregulated in the
aforementioned malignancies are predicted to target KLKs.
The experimentally validated interactions include those
between miR-331-3p and KLK4, miR-143 and KLK10,
miR-224 and both KLK1 and KLK10, let-7f and both KLK6
and KLK10, miR-516a and KLK10, as well as between mem-
bers of the miR-99 family and KLK3 [14,69]. In ovarian and
prostate cancers, a significant negative correlation between
the expression levels of miRNAs and their target KLKs has
been documented [14,66,69]. For example, a negative correlation
between the expression levels of miR-224 and its predicted
target KLK15 has been reported in prostate cancer [69].
Interestingly, both KLK15 and miR-224 have been repeatedly
proposed by independent researchers as important biomarkers
of unfavorable and favorable, respectively, prognosis for
prostate cancer patients [70–73]. We believe that the combina-
tion of miRNA and KLK expression into informative
Review Scorilas & Mavridis
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diagnostic/prognostic scores can constitute a novel approach
in stratifying and translating the heterogeneity of human
malignancies to meaningful clinical information.
The KLK locus contains multiple CpG islands, and DNA
methylation represents a suggested mechanism of KLK tran-
scriptional regulation for certain gene members (e.g., KLK6,
KLK10, KLK1, KLK11, KLK12 and KLK13). The decreased
expression of certain KLKs observed in some human malig-
nancies (e.g., KLK6 in breast cancer, KLK10 in NSCLC) is
closely associated with CpG island hypermethylation [14,74].
KLK10 exon 3 methylation is associated with poor prognosis
in acute lymphoblastic leukemia and breast cancer, while it is
also considered as an indicator of advanced disease in
NSCLC [14]. A recent study shows that low KLK10 methyla-
tion levels are associated with biochemical relapse in prostate
cancer patients [75].
There is even more to KLKs than their tumor marker
potential: the role of KLKs as biomarkers in
nonmalignant diseases
Without doubt, most of the studies regarding the biomarker
capacity of KLKs concern human malignancies. Nonetheless,
studies addressing the potential role of KLKs in the molecular
diagnostics of nonmalignant diseases are also intriguing.
The deregulation of KLK levels has been comprehensively
reported in nonmalignant diseases of the CNS [11,76]. Serum
and/or cerebrospinal fluid (CSF) KLK levels could be consid-
ered as biomarkers for major CNS diseases.
In Alzheimer’s disease (AD), CSF levels of KLK10 increase,
while those of KLK7 decrease. Lower KLK7 CSF levels are asso-
ciated with the presence of ApoE4 alleles, a risk factor of AD [77].
Both whole blood and CSF levels of KLK6 were initially reported
to be increased in AD patients compared with normal con-
trols [78]. Contrariwise, it has been recently shown that patients
with synucleinopathy showed lower KLK6 CSF levels compared
with controls and AD patients; no difference was found in
KLK6 CSF levels between AD and control samples in the same
study [79]. KLK6 CSF and plasma levels are positively correlated
with age in normal individuals, and this association is lost [80] or
even inverted [81] in AD patients. Decreased KLK6 CSF levels
have been proposed as a risk factor for AD development [80].
Interestingly, KLK6 plasma concentrations can be used for the
discrimination between AD patients and individuals without
neurodegenerative dementia [81], as well as for calculating the risk
for progression of mild cognitive impairment to dementia with
vascular component or AD [82]. Furthermore, patients with fron-
totemporal dementia exhibit decreased KLK6, KLK7 and
KLK10 CSF levels compared with control subjects [77].
Serum KLK6 levels are increased after traumatic brain
injury [83] and in postpolio syndrome [84], whereas they are
decreased in a life-threatening condition known as aneurysmal
subarachnoid hemorrhage, with the lowest levels measured in
patients with worse outcome [85].
Aberrant KLK levels are also found in multiple sclerosis
(MS). Interestingly, KLK6 participates directly in the
pathogenesis of MS by cleaving basic myelin proteins [17,76]. An
initial study has shown that serum KLK1 and KLK6 levels are
elevated in MS patients and are associated with secondary pro-
gressive MS and expanded disability status scale scores [86].
Patients diagnosed with advanced MS exhibit elevated KLK6
CSF levels compared with neurological controls [87]. On the
contrary, three recent proteomic studies have shown that
KLK6 is significantly decreased in the CSF of patients with
relapsing–remitting MS compared with other neurological dis-
ease controls [88–90]. Significantly increased anti-KLK11 anti-
body levels (82% sensitivity, 94% specificity) are found in the
serum of patients diagnosed with Sjo¨gren’s syndrome, another
autoimmune-mediated disease [91].
One of the well-studied physiological roles of KLKs is their
central contribution in maintaining skin homeostasis and des-
quamation (mainly for KLK5, KLK7 and KLK14). Studies on
Netherton syndrome, a rare genetic skin disease linked with
mutations in the SPINK5 gene encoding for the inhibitor
LEKTI that blocks KLK activity, have shown that the lack of
LEKTI causes KLK overactivation, over-desquamation of cor-
neocytes, inflammation and ultimately severe skin dysfunction
[19–22,92]. Regarding the biomarker capacity of KLKs in skin dis-
eases, they may hold promise as biomarkers for psoriasis.
KLK6 and KLK8 are increased in psoriatic arthritis synovial
fluid compared with noninflammatory osteoarthritis. KLK8
serum levels are also elevated in psoriatic disease and are inde-
pendently associated with cutaneous psoriasis activity, but not
with arthritic disease activity. Consequently, KLK8 could con-
stitute a novel surrogate molecular marker for estimating cuta-
neous psoriasis severity and monitoring therapeutic response
[93]. KLK10 and KLK13 serum levels are also correlated with
the severity of skin lesions in psoriasis. Interestingly, KLK5 and
KLK11 concentrations are lower in the serum of psoriasis vul-
garis and arthropathic psoriasis patients compared with normal
individuals and are significantly decreased after therapy [94]. As
far as atopic dermatitis is concerned, serum KLK8 levels are
increased, whereas KLK5 and KLK11 levels are decreased [95]; a
KLK7 polymorphism (AACC insertion in the 3´-UTR) has
also been associated with this disease [96].
KLK SNPs: biomarker potential deriving from yet
another facet of KLKs association with human
pathology
A plethora of data demonstrates the linkage between SNPs
within the KLK locus and a wide variety of diseases [96]. In
the nonmalignant setting, KLK1 SNPs are associated with
hypertension (rs3212816, rs5517), cerebral hemorrhage
(rs5517) and cardiovascular disease (rs5515), a KLK2 SNP is
related to male infertility (rs2664155), a KLK4 mutation has
been identified as causing event of a tooth disorder (muta-
tion: g.2142 G > A, Trp153Stop) and certain KLK8 SNPs
have been linked with intracranial aneurysm (rs1722561,
rs1701946) [96] and bipolar disorder (rs1612902) [97]. Pros-
tate cancer has been the cornerstone of KLK-related SNPs
research, perhaps due to the importance of PSA. KLK2
Predictions for the future of KLKs in molecular diagnostics Review
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(rs198977, rs2664155, rs1506684), KLK3 (e.g., rs266882,
rs1058205, rs266870, rs2659122), KLK4 (e.g., rs7248321,
rs1654551, rs1701927, rs806019) KLK10 (rs3745535) and
KLK12 (rs3865443) SNPs have been associated with prostate
cancer risk, KLK3 (e.g., rs266882, rs2735839, rs17632542),
KLK4 (rs198968), KLK14 (rs17728459, rs35287116) and
KLK15 (rs2659056) SNPs with disease aggressiveness, two
KLK3 SNPs (rs61752561, rs2735839) with patients’ survival
and a KLK2 SNP (rs198977) with biochemical recurrence.
Likewise, KLK2 (rs198977) and KLK4 (rs806019) SNPs
have been associated with breast cancer risk, a KLK3 SNP
was related to less aggressive breast cancer (rs11575894) as
well as KLK3 (rs11084033) and KLK15 (rs266851) SNPs
were linked with ovarian cancer survival [96,98–100].
Even though individual KLK SNPs may not be likely to be
used as a standalone test in future molecular diagnostics, the
multifactorial approach seems, once again, to be more realistic.
The combination of KLK SNPs with these of other loci and/or
with other conventional clinicopathological data may form the
basis of a rapid, easily performed DNA-based clinical test.
Toward this direction, it has already been shown that a KLK2
SNP (rs198977) can be combined with clinical data or serum
KLK2 levels in order to improve the prediction of biochemical
relapse [96] or to enhance prostate cancer detection [100], respec-
tively. Other KLK SNPs can also aid in prostate cancer risk
prediction and therapeutic decision making though their incor-
poration into multifactorial models [101].
Expert commentary
The use of PSA measurements as a prostate cancer biomarker
was a major breakthrough for the practice of oncology.
Nonetheless, its extensive use as screening tool in asymptom-
atic men introduced complexities in prostate cancer manage-
ment. Without intending to overlook the benefits that PSA
has provided regarding the detection of prostate cancer in
early stages, it should be noted that PSA-driven overdiagnosis
and overtreatment are issues that still remain to be tack-
led [23,30]. The current challenge is to identify multifactorial
biomarker panels that will provide clear advantages over indi-
vidual biomarkers such as PSA. The application of KLK-
based biomarker panels could assist in the decision-making
processes primarily for prostate cancer and, in the long term,
for other malignancies as well.
Data from the ‘four-kallikrein panel’ approach are very
encouraging toward the reduction of unnecessary prostate
biopsies [45–49]. Ovarian, lung and colorectal cancer manage-
ment could also be enhanced by multifactorial biomarker
panels that include multiple KLK members [54–62]. The
amount of KLK-derived information that can be combined
is enormous and has been made available through decades
of, still ongoing, translational research. KLK expression
(mRNA and protein levels), KLK-targeting miRNAs, SNPs
found within the KLK locus and the methylation status of
KLK genes are examples of detailed molecular data that
could be combined with traditional clinicopathological
factors. This multifaceted approach can enhance the diagnos-
tic, prognostic, predictive and/or treatment monitoring
potency of the one-sided procedures that are currently fol-
lowed throughout cancer patients’ management. Well-
designed and established assays are already available for KLK
assessment at the protein (ELISA, immunohistochemistry),
RNA (qPCRs for mRNA and KLK-targeting miRNAs) and
DNA (quantitative methylation methods, sequencing for
SNPs) levels. These easily performed assays can be cost-
effectively used in routine clinical practice. Interestingly,
KLK levels can be also measured in the serum and CSF of
patients suffering from nonmalignant diseases. This has
opened new opportunities for the consideration of KLKs as
biomarkers for major neurodegenerative and neuroinflamma-
tory diseases such as AD and MS [78,81,86,87].
Five-year view
It is rather unlikely that any single-biomarker test could
address the heterogeneity observed, in terms of biological and
clinical manifestation, in most human malignancies. Combin-
ing multiple biomarkers with conventional, yet strong, indi-
cators can significantly improve the accuracy of molecular
diagnostics. The FDA clearance of the multifactorial ROMA
score and OVA1 panel for ovarian cancer enhances this
notion further [24].
The significance of several KLK members as individual bio-
markers has been corroborated by independent research groups
[7,8,12,41,42]. Nonetheless, the need for multicentric large-scale
validation still exists. We believe that there is a niche for addi-
tional KLKs in the treatment decision making of cancer
patients and that this can be achieved through their integration
in well-defined biomarker panels. Based on the repeatedly vali-
dated and straightforward results that have been reported [45–49],
it is highly probable that the ‘four-kallikrein panel’ will be
eventually introduced in clinical practice for prostate cancer.
The recent FDA approvals for prostate health index (based on
serum-2pro-, total- and free PSA measurements) and urinary
PCA3 score highlight the intense medical need for improving
decisions regarding prostate cancer management.
Current and future trends in KLK research, such as the
elucidation of miRNA–KLKs axis of interaction, deciphering
the KLK-methylation patterns, characterization of KLK SNPs,
discovery of novel KLK mRNA transcripts, determination of
glycosylated KLK isoforms – especially for KLK3 [102] and
KLK6 [103] – could help in transforming the envisagement of
the incorporation of additional KLKs in future molecular diag-
nostics into a clinical reality.
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Key issues
• The Kallikrein-related peptidase (KLK) gene family encodes for 15 secreted serine proteases, many of which have been described as
cancer-related molecules.
• KLK3 (also known as prostate-specific antigen [PSA]) represents the most renowned member of the KLK family. The wide application of
PSA as a biomarker for prostate cancer screening has provided notable benefits, such as the detection of prostate cancer at early stages
and a, much debated, decrease in mortality rates.
• The benefits of PSA testing came with the complications of overdiagnosis and overtreatment. Thus, novel prostate cancer biomarkers
should be introduced in order to reduce the amount of unnecessary biopsies.
• Individual KLK members have been described as biomarkers for the majority of human malignancies including prostate, ovarian, breast,
lung and colorectal cancers.
• The incorporation of KLKs into multifaceted biomarker panels provides enhanced diagnostic, prognostic and predictive accuracy in
several human malignancies. The most successful example is that of the ‘four-kallikrein panel’ for prostate cancer, which has great
dynamics for introduction into future clinical practice.
• Multifactorial KLK-driven biomarker panels have also been proposed for ovarian, lung and colorectal cancer decision making.
• KLK-derived information that could be combined in biomarker panels includes data from the KLK expression profiling (mRNA and/or
protein levels), KLK-targeting miRNAs, SNPs found within the KLK locus and methylation status of KLK genes.
• KLKs are also regarded as promising biomarkers for nonmalignant diseases such as Alzheimer’s disease and multiple sclerosis.
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